Labcorp chief legal officer Kyle sells $26,329 in common stock.
Labcorp's Chief Legal Officer, Kathryn W. Kyle, sold 92 shares of common stock worth $26,329 on July 2, 2026, as part of a Rule 10b5-1 trading plan. This transaction followed the vesting of 256 Restricted Stock Units on July 1, 2026, with concurrent disposal of 73 shares to cover tax obligations. After these transactions, Ms. Kyle holds 3,904.4574 shares and 2,008 RSUs, while Labcorp (NASDAQ:LH) shares are near their 52-week high, and the company is deemed undervalued by InvestingPro.
Labcorp EVP Bryan Vaughn sells $66,968 in common stock
Bryan T. Vaughn, Executive Vice President and President of Diagnostics at Labcorp Holdings Inc., sold 234 shares of common stock for approximately $66,968 on July 2, 2026, following the vesting of RSUs and a tax-related disposition. After these transactions, Vaughn directly holds 6,745.5702 shares and 3,704 Restricted Stock Units. InvestingPro analysis suggests Labcorp is undervalued, trading near its 52-week high, and the company recently reported strong Q1 2026 results and launched new diagnostic products, including an FDA-approved colorectal cancer screening test.
Labcorp chief legal officer Kyle sells $26,329 in common stock. By Investing.com
Labcorp's Chief Legal Officer, Kathryn W. Kyle, sold 92 shares of common stock for $26,329 on July 2, 2026, as part of a Rule 10b5-1 trading plan. This sale occurred while Labcorp shares were near their 52-week high. The transaction followed the vesting of 256 Restricted Stock Units, with some shares disposed of to cover tax obligations.
Labcorp EVP Bryan Vaughn sells $66,968 in common stock
Bryan T. Vaughn, EVP and President of Diagnostics at Labcorp, sold 234 shares of common stock for $66,968 on July 2, 2026, following the vesting of Restricted
Labcorp (NYSE: LH) legal chief sells shares, exercises 256 stock units
Labcorp EVP and Chief Legal Officer Kathryn W. Kyle reported exercising 256 Restricted Stock Units and an open-market sale of 92 common shares at $286.19 per share under a pre-arranged Rule 10b5-1 trading plan. After these transactions, she directly holds approximately 3,904.4574 common shares and 2,008 Restricted Stock Units. The filing also noted 73 shares were withheld to cover tax obligations.
Labcorp (LH) EVP sells shares after RSU vesting under Rule 10b5-1 plan
Labcorp EVP Bryan T. Vaughn sold 234 common shares at $286.19 each on July 2, 2026, following the vesting of 327 Restricted Stock Units on July 1, 2026. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan, with 93 shares withheld for tax obligations. After the sale, Vaughn holds 6,745.5702 Labcorp shares and 3,704 Restricted Stock Units.
Labcorp Holdings (LH) Expands Cancer And Liver Testing, Is It Fully Priced?
Labcorp Holdings (LH) is gaining attention due to recent advancements in cancer and liver testing, including the nationwide Medicare-covered launch of its ColoSense colorectal screening kit. Despite strong share price performance, the company is considered approximately 7.5% undervalued with a fair value estimate of $310, driven by anticipated revenue growth from strategic collaborations and innovative test introductions. However, potential risks from tariffs and regulatory shifts could impact this positive outlook.
Labcorp Pixel by Labcorp - At-home sample collection quietly goes mainstream
Labcorp Pixel by Labcorp is a direct-to-consumer platform enabling at-home sample collection for various lab tests in the US. This initiative allows patients to access Labcorp’s clinical lab network without a doctor's visit, leveraging existing infrastructure to cater to the growing demand for home-based health monitoring. The service is strategically important for Labcorp's expansion beyond traditional diagnostics into consumer and employer markets, despite operating in a competitive landscape.
GRAL - GRAIL Inc Volatility & Greeks
This article provides a detailed financial overview of GRAIL Inc. (GRAL), including key metrics such as market capitalization, income, sales, various performance ratios, and stock performance indicators. It also lists insider and institutional ownership, analyst recommendations, and volatility measures. The data reflects the company's financial health, operational efficiency, and market sentiment, with the last close at $68.95.
Why Labcorp Holdings (LH) Is Up 7.7% After Expanding Advanced At-Home and Blood-Based Diagnostics
Labcorp (LH) saw its stock rise by 7.7% after announcing new peer-reviewed evidence supporting its MVX and NIS2+ blood tests for metabolic liver disease, and the nationwide launch of ColoSense, an FDA-approved home colorectal cancer screening test now covered by Medicare. These developments strengthen Labcorp's position in early detection diagnostics and could influence its long-term investment narrative, projecting $16.3 billion revenue and $1.3 billion earnings by 2029. Despite positive growth in advanced testing, investors are advised to consider potential reimbursement changes and pricing pressures that could impact future financial performance.
OPK - Opko Health Inc Options
This article provides a comprehensive overview of Opko Health Inc. (OPK) stock, including its latest closing price, key financial metrics, performance indicators, and ownership details. It details statistics such as market capitalization, income, sales, P/E ratio, EPS, insider and institutional ownership, and various performance percentages over different periods.
Labcorp launches FDA-cleared blood test for Alzheimer's disease
Labcorp has introduced an FDA-cleared blood test for Alzheimer's disease, which aims to provide an accessible and less invasive diagnostic option compared to traditional methods like PET scans and cerebrospinal fluid tests. The test detects amyloid beta abnormalities and is intended for use in adults experiencing cognitive decline, helping to guide treatment decisions and potentially accelerate research. This development marks a significant step towards broader access to Alzheimer's diagnostics.
FLGT - Fulgent Genetics Inc Forecast, Target Price
This article provides a detailed financial overview and forecast for Fulgent Genetics Inc (FLGT). It includes key metrics such as market capitalization, income, sales, earnings per share, and stock performance indicators. The report also highlights analyst recommendations and a target price for the company's stock.
Why Labcorp Holdings (LH) Is Up 7.7% After Expanding Advanced At-Home and Blood-Based Diagnostics
Labcorp Holdings (LH) saw a 7.7% stock increase following its expansion of advanced at-home and blood-based diagnostics. The company highlighted new peer-reviewed evidence for its MVX and NIS2+ blood tests for metabolic liver disease and launched ColoSense, an FDA-approved RNA-based colorectal cancer screening test now covered for Medicare beneficiaries. These developments aim to simplify early detection of liver and colorectal diseases, potentially strengthening Labcorp's long-term investment narrative.
Why Labcorp Holdings (LH) Is Up 7.7% After Expanding Advanced At-Home and Blood-Based Diagnostics
Labcorp (LH) saw its stock rise by 7.7% after announcing new peer-reviewed evidence for its MVX and NIS2+ blood tests for metabolic liver disease and the nationwide U.S. launch of ColoSense, an FDA-approved, RNA-based at-home colorectal cancer screening test now covered by Medicare. These developments underscore Labcorp's focus on less invasive and accessible diagnostics for early detection of liver and colorectal diseases. The company's strategy involves expanding its test breadth to capture more volume and offset reimbursement pressures, though investors are advised to also consider potential impacts from changing reimbursement policies.
NTRA - Natera Inc Options
This article provides a detailed financial overview of Natera Inc. (NTRA), including its stock performance, key financial metrics, insider and institutional ownership, and analyst recommendations. It highlights the company's valuation ratios, growth rates, and market indicators as of July 2, 2024.
Is NeoGenomics (NEO) Quietly Reframing Its Oncology Data Strategy With Starrett’s Board Appointment?
NeoGenomics (NEO) has appointed Carolyn Starrett, a former Flatiron Health CEO known for her expertise in AI and healthcare data, to its Board of Directors. This move, combined with its Epic Aura integration, suggests NeoGenomics is enhancing its oncology data strategy to differentiate its services and improve long-term growth. While this could lead to more predictable growth and narrower losses by leveraging AI and real-world data, investors should be aware of the inherent risks, including ongoing losses and revenue volatility from pharma and biotech demand.
Labcorp Holdings Inc. stock underperforms Thursday when compared to competitors despite daily gains
Labcorp Holdings Inc. (LH) stock gained 1.09% on Thursday, closing at $286.98, marking its eighth consecutive day of increases. Despite this daily gain, the stock underperformed compared to its competitors, even as the broader market saw mixed results with the S&P 500 remaining mostly unchanged and the Dow Jones Industrial Average rising.
Guardant’s Shield colon cancer blood test snags UnitedHealth coverage
Guardant Health's Shield test for colorectal cancer has secured coverage from UnitedHealth, marking the first time a major private U.S. health insurer will reimburse for the screening. This decision expands access to approximately 100 million Americans and is considered a "watershed moment" for liquid biopsy-based cancer screening. The Shield test is the first FDA-approved blood test for primary colorectal cancer screening in average-risk adults aged 45 and older, offering an alternative to stool-based tests.
Medtronic starts to notify people affected by cyberattack
Medtronic has begun notifying individuals potentially affected by a cyberattack disclosed over two months ago, offering complimentary credit monitoring and identity theft services. The company states there is no evidence the accessed data has been publicly posted, and no impact on product security or patient safety has been identified. This incident follows a string of cyberattacks on other medtech companies, including Stryker, Intuitive Surgical, and iRhythm, highlighting an ongoing industry-wide vulnerability.
[144] LABCORP HOLDINGS INC. SEC Filing
This SEC filing (Form 144) for Labcorp Holdings Inc. (LH) details a proposed sale of securities, specifically 234 shares of common stock acquired through restricted stock vesting on July 1, 2026. The aggregate market value of the shares to be sold is $66968.46, with the sale expected around July 2, 2026, on the NYSE via Fidelity Brokerage Services LLC. The filing confirms no previous sales by the filer in the past three months and includes a standard representation that the filer has no knowledge of undisclosed material adverse information.
Here's What to Expect From Labcorp Holdings’ Next Earnings Report
Labcorp Holdings Inc. (LH) is set to release its second-quarter earnings on July 30, 2026, with analysts anticipating a 10.1% increase in EPS to $4.79. Despite consistently beating Wall Street estimates and strong analyst ratings, LH stock has underperformed the broader market due to concerns over weak long-term growth, declining revenue, and modest organic growth. The average analyst price target suggests an 8.9% upside from current levels.
Waters to hold Q2 2026 results call Aug. 4, webcast set
Waters Corporation (NYSE: WAT) has scheduled its second-quarter 2026 financial results conference call for Tuesday, August 4, 2026, at 8:00 a.m. Eastern Time. A live webcast and replay of the presentation will be available on the company's Investor Relations website until at least September 1, 2026. This announcement provides key financial reporting dates for investors and signals a period of updates following recent corporate activities.
Labcorp Holdings Inc. stock underperforms Wednesday when compared to competitors despite daily gains
Labcorp Holdings Inc. (LH) stock rallied 1.39% to $283.88 on Wednesday, marking its seventh consecutive day of gains. Despite this rise, the stock underperformed compared to the broader market, as the S&P 500 Index (SPX) fell 0.22% and the Dow Jones Industrial Average (DJIA) fell 0.03%.
OneTest growth vision: 20/20 Biolabs (AIDX) targets Medicare MCED market
20/20 Biolabs (AIDX) outlined its OneTest multi-cancer early detection strategy, which includes a focus on future Medicare reimbursement and a protein biomarker-based test. The company is aligning its strategy with the new Multi-Cancer Early Detection Screening Coverage Act, aiming for Medicare coverage of MCED tests starting in 2028, contingent on FDA authorization and CMS clinical appropriateness. The presentation also detailed an M&A strategy targeting health-and-wellness businesses and included hypothetical revenue projections and a royalty pool for "data investors."
Labcorp to Announce Second Quarter 2026 Financial Results on Jul
Labcorp (NYSE: LH) will release its second quarter 2026 financial results before the market opens on Thursday, July 30, 2026. The company will host a webcast at 9:00 a.m. ET on the same day to discuss the results. The earnings press release and replay of the webcast will be available on the Labcorp Investor Relations website.
Labcorp to Announce Second Quarter 2026 Financial Results on July 30, 2026
Labcorp (NYSE: LH) will announce its second quarter 2026 financial results on July 30, 2026. The company will host a conference call and webcast at 9:00 a.m. EDT on the same day to discuss the results and provide an update on its business. Related materials will be available on the company's investor relations website prior to the call.
Form 144 LABCORP HOLDINGS INC. For: 1 July By Investing.com
This article announces that Labcorp Holdings Inc. filed Form 144 for July 1st. It also includes general market data, popular news headlines, and trending stock information from the Investing.com platform. The content notes that Labcorp Holdings' stock symbol is LH and it saw a 1.39% increase.
Form 144 LABCORP HOLDINGS INC. For: 1 July By Investing.com
This article announces the filing of Form 144 for LABCORP HOLDINGS INC. on July 1st. It also includes various market data, such as indices, commodities, and bond yields, and lists trending and most active stocks. The article is brief and primarily serves as a notification regarding the Form 144 filing.
Baird initiates Abbott stock coverage with Outperform rating
Baird has initiated coverage on Abbott Laboratories (NYSE:ABT) with an Outperform rating and a price target of $121, indicating a 33% upside. The firm anticipates steady 6-8% top-line and earnings growth for Abbott, driven by its strong medical devices business and strategic integrations. Abbott is considered undervalued, a prominent player in its industry, and has consistently raised its dividend for 12 years.
Labcorp to Announce Second Quarter 2026 Financial Results on July 30, 2026
Labcorp (NYSE: LH) will release its second quarter 2026 financial results before the market opens on Thursday, July 30, 2026. The company will host a webcast at 9:00 a.m. ET on the same day to discuss the results. The earnings press release and webcast link will be available on Labcorp's Investor Relations website.
Labcorp to report Q2 2026 results July 30; webcast at 9:00 a.m. ET
Labcorp (LH) will release its second-quarter 2026 financial results before market open on July 30, 2026. The company will host a webcast at 9:00 a.m. ET on the same day to discuss these results. An earnings press release and financial information will be available on Labcorp's Investor Relations website, with a webcast replay accessible for one year.
Labcorp Holdings Inc. (LH) Announces Upcoming Release of Q2 2026 Financial Results
Labcorp Holdings Inc. (LH) has announced that it will release its second-quarter 2026 financial results on Thursday, July 30, 2026, before the market opens. Following the release, the company will host a conference call and webcast to discuss the results at 9:00 a.m. ET. Investors and analysts can access the earnings materials on Labcorp's Investor Relations website for insights into the company's performance and strategic direction.
MYGN - Myriad Genetics Inc Latest SEC Filings
This article provides the latest SEC filings and detailed financial data for Myriad Genetics Inc. (MYGN), including key metrics like market capitalization, income, sales, P/E ratios, and stock performance data. It also lists insider and institutional ownership, profitability margins, and various technical indicators, offering a comprehensive snapshot of the company's financial health and stock activity.
Select Medical Holdings Corporation Acquired by Consortium Led by Robert A. Ortenzio, Martin F. Jackson, and WCAS
Select Medical (NYSE: SEM) has completed its acquisition by a consortium led by Robert A. Ortenzio, Martin F. Jackson, and Welsh, Carson, Anderson & Stowe for $16.50 per share, valuing the company at $3.9 billion. This price represents an 18% premium to the unaffected share price and a 25% premium to the 90-day volume-weighted average price as of November 24, 2025. Effective July 1, 2026, Select Medical will be delisted from the NYSE, with current leadership remaining in place.
Labcorp (NYSE: LH) sets July 30, 2026 Q2 earnings webcast
Labcorp (NYSE: LH) announced it will release its financial results for the second quarter of 2026 before the market opens on Thursday, July 30, 2026. The company will also host a webcast at 9:00 a.m. ET on the same day to discuss these results. Investors can find the earnings press release and webcast link in the "News & Events" section of Labcorp's investor relations website, with a replay available for one year.
Labcorp will post Q2 results July 30, then host a 9 a.m. webcast
Labcorp (NYSE: LH) is scheduled to release its second quarter 2026 financial results before market open on Thursday, July 30, 2026. The company will also host a webcast at 9:00 a.m. ET to discuss the results, with related materials and a replay available on its investor relations website for one year. Historically, similar announcements have correlated with a modest positive price reaction for LH stock.
MKS (MKSI) Advanced on Sales Strength
MKS Inc. (MKSI) was a top contributor to the Madison Mid Cap Fund in Q1 2026, with its shares advancing due to improved sales and profits driven by increased orders in the semi-cap industry and demand for AI-related applications. While the fund trimmed its position due to valuation, MKSI posted a significant one-month return of 25.54% and a 313.03% gain over 52 weeks. The article notes that 71 hedge funds held MKSI at the end of Q1 2026, and the company reported Q1 revenue of $1.08 billion, up 15% year-over-year.
Labcorp consensus stays steady, S&P 500 peer group frames the stock
Labcorp (US50540R4092) maintains a stable analyst consensus as it begins the week, positioning itself within the S&P 500 healthcare sector. The company's performance is driven by its diagnostic and central lab services, with investors keenly observing upcoming earnings and broader sector trends. Analysts' price targets are typically based on mid-to-high single-digit revenue growth and mid-teen operating margins for its core laboratory business.
Labcorp Holdings Inc. stock outperforms competitors on strong trading day
Shares of Labcorp Holdings Inc. (LH) rose 2.99% on Monday, closing at $279.58, and outperforming major indices like the S&P 500 and the Dow Jones Industrial Average. This marks the fifth consecutive day of gains for the stock. The positive performance occurred during a strong trading session for the overall market.
Labcorp looks to next earnings date, shares trade steadily on NYSE
Labcorp (US50540R4092) is drawing investor attention as it approaches its next quarterly earnings update, with its shares trading steadily on the NYSE. The company operates in the diagnostics and lab services sector, competing with major players like Quest Diagnostics and Thermo Fisher Scientific, and provides a range of clinical laboratory testing and diagnostic services. Its shares last closed at $272.09 on June 26, 2026, positioning Labcorp as a significant entity within the large-cap US healthcare market.
Quest Diagnostics earnings calendar in focus, shares trade steadily on the NYSE
Quest Diagnostics' upcoming quarterly earnings are drawing investor attention as the healthcare diagnostics group prepares for its next update on the NYSE. Analysts largely view the shares as fairly valued, anticipating stable revenue growth and consistent margin profiles, reflecting steady demand for diagnostic testing services. The company's performance, which reports on routine and advanced diagnostics, is a key indicator for broader healthcare spending and trends in the US.
Guardant Health (GH) Stock After 193% One-Year Gain Is The Rally Running Out Of Room
Guardant Health (GH) has seen a 193% one-year gain, prompting questions about its current valuation. A Discounted Cash Flow (DCF) analysis suggests the stock is currently trading at a small 6.2% discount to its intrinsic value, indicating it is "about right" for its current price of $149. However, its Price/Sales (P/S) ratio of 18.32x is significantly higher than the industry average and Simply Wall St's Fair Ratio of 7.86x, suggesting the stock might be overvalued based on this metric.
Charles River Laboratories strategy focus, S&P 500 health stock in contract research
Charles River Laboratories is a key US health-sector contract research provider listed on the NYSE and part of the S&P 500 index. The company specializes in preclinical and clinical contract research services, helping pharmaceutical and biotech firms outsource essential development steps, particularly in early-stage research and animal models for drug development. Its strategy focuses on being a full-service partner, leveraging structural outsourcing trends to achieve scale efficiencies and maintain strong client relationships.
Labcorp rolls out colorectal cancer screening test nationwide
Labcorp has launched its ColoSense colorectal cancer screening test nationwide, positioning it as a competitor to Exact Sciences' Cologuard. The rollout follows CMS approval for coverage and the American Cancer Society's endorsement. ColoSense differentiates itself with a simplified stool collection process, addressing user discomfort associated with Cologuard's method.
Labcorp focuses on long-term strategy, shares supported by healthcare demand
Labcorp is undergoing a multi-year transformation of its diagnostics and drug-development businesses, supported by steady healthcare demand and insurance spending. The company reported first-quarter 2026 revenue of approximately $3.2 billion, driven by strong testing volumes and central laboratory services for pharmaceutical trials, with a focus on high-growth areas like specialty diagnostics. Labcorp (LH) shares recently traded around $271 on the NYSE, with a market capitalization near $22 billion.
Price to sales forward of Labcorp Holdings Inc. – BOATS:LH
This article provides the "Price to sales forward" financial metric for Labcorp Holdings Inc. (LH) under the Blue Ocean Alternative Trade System (BOATS) on TradingView. It highlights the company's financial data within the Health Services sector.
Labcorp Holdings Inc. Actuals & Estimates (NYSE:LH)
This article from TradingView provides a detailed financial overview of Labcorp Holdings Inc. (NYSE:LH), including current stock performance, analyst estimates, historical prices, market capitalization, earnings reports, revenue, net income, dividends, and volatility. It highlights that LH stock has seen recent increases and provides future earnings and revenue expectations.
Labcorp Holdings Inc. stock underperforms Friday when compared to competitors despite daily gains
Labcorp Holdings Inc. (LH) shares advanced 1.93% on Friday, closing at $271.47, marking its fourth consecutive day of gains. However, this performance underperformed the broader market, as the S&P 500 Index (SPX) fell 0.05% and the Dow Jones Industrial Average (DJIA) fell 0.09% during the same trading session.
Labcorp outlines specialty testing growth, shares trade in tight NYSE range
Labcorp (US50540R4092) is highlighting its specialty testing and various partnerships as key drivers for growth. The shares are currently trading in a tight range on the NYSE, demonstrating a solid earnings yield compared to the broader healthcare sector, and analysts like Zacks give the company a "Buy" rating. The company's market capitalization stands above 21 billion dollars, firmly placing it among mid-to-large healthcare providers in the US equity market.
